2012-09-18 08:08:19 - Recently published research from Global Markets Direct, "Atopic Dermatitis (Eczema) - Pipeline Review, H2 2012", is now available at Fast Market Research
Global Markets Direct's, 'Atopic Dermatitis (Eczema) - Pipeline Review, H2 2012', provides an overview of the Atopic Dermatitis (Eczema) therapeutic pipeline. This report provides information on the therapeutic development for Atopic Dermatitis (Eczema), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Atopic Dermatitis (Eczema). 'Atopic Dermatitis (Eczema) - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.
Note*: Certain sections in the report may be removed or altered based on the availability and
relevance of data for the indicated disease.
Full Report Details at
- www.fastmr.com/prod/463847_atopic_dermatitis_eczema_pipeline_rev ..
* A snapshot of the global therapeutic scenario for Atopic Dermatitis (Eczema).
* A review of the Atopic Dermatitis (Eczema) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
* Coverage of products based on various stages of development ranging from discovery till registration stages.
* A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
* Coverage of the Atopic Dermatitis (Eczema) pipeline on the basis of route of administration and molecule type.
* Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
* Key discontinued pipeline projects.
* Latest news and deals relating to the products.
Reasons to buy
* Identify and understand important and diverse types of therapeutics under development for Atopic Dermatitis (Eczema).
* Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
* Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
* Devise corrective measures for pipeline projects by understanding Atopic Dermatitis (Eczema) pipeline depth and focus of Atopic Dermatitis (Eczema) therapeutics.
* Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
* Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Atopic Dermatitis (Eczema) Therapeutic Products under Development, Key Players in Atopic Dermatitis (Eczema) Therapeutics, Atopic Dermatitis (Eczema) Pipeline Overview, Atopic Dermatitis (Eczema) Pipeline, Atopic Dermatitis (Eczema) Pipeline Assessment
Partial Table of Contents:
Table of Contents
Table of Contents
List of Tables
List of Figures
Global Markets Direct Report Coverage
Atopic Dermatitis (Eczema) Overview
An Overview of Pipeline Products for Atopic Dermatitis (Eczema)
Atopic Dermatitis (Eczema) Therapeutics under Development by Companies
Atopic Dermatitis (Eczema) Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Mid Clinical Stage Products
Early Clinical Stage Products
Discovery and Pre-Clinical Stage Products
Atopic Dermatitis (Eczema) Therapeutics - Products under Development by Companies
Atopic Dermatitis (Eczema) Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Atopic Dermatitis (Eczema) Therapeutics Development
Bristol-Myers Squibb Company
Bayer HealthCare AG
Daiichi Sankyo Company, Ltd
Eisai Co., Ltd.
LEO Pharma A/S
Nippon Shinyaku Co., Ltd.
Regeneron Pharmaceuticals, Inc.
ProMetic Life Sciences Inc.
Hanall Pharmaceutical Co., Ltd.
AnGes MG, Inc.
Provectus Pharmaceuticals, Inc.
Proximagen Neuroscience plc.
R-Tech Ueno, Ltd.
Paloma Pharmaceuticals, Inc.
Asubio Pharmaceuticals, Inc.
Palau Pharma S.A
MIKA Pharma GmbH
CREABILIS Therapeutics S.r.l.
Anacor Pharmaceuticals, Inc.
JADO Technologies GmbH.
Hawthorn Pharmaceuticals, Inc.
Melior Discovery, Inc.
Syntrix Biosystems, Inc.
Welichem Biotech Inc.
Cutanea Life Sciences
Action Pharma A/S
SWITCH Biotech LLC
Pharis Biotec GmbH
Viromed Co., Ltd.
Celtic Pharmaceutical Holdings L.P.
Atopic Dermatitis (Eczema) - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
GW870086 - Drug Profile
BMS-981164 - Drug Profile
MK52 - Drug Profile
MK51 - Drug Profile
Full Table of Contents is available at:
About Global Markets Direct
Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. View more research from Global Markets Direct at www.fastmr.com/catalog/publishers.aspx?pubid=1033
About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.
For more information about these or related research reports, please visit our website at www.fastmr.com
or call us at 1.800.844.8156.